Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients

European Respiratory Journal

Volumn 44, Issue 4, 2014, Pages 963-972

  Hao, Yan Jie ^a   Jiang, Xin ^b   Zhou, Wei ^a   Wang, Yong ^c   Gao, Lan ^a   Wang, Yu ^a   Li, Guang Tao ^a   Hong, Tao ^a   Huo, Yong ^a   Jing, Zhi Cheng ^b   Zhang, Zhuo Li ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; ILOPROST; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHODIESTERASE INHIBITOR; PROSTANOID; SILDENAFIL; SMALL NUCLEAR RIBONUCLEOPROTEIN; VARDENAFIL; WARFARIN;

ADULT; ADULT ONSET STILL DISEASE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CAUSE OF DEATH; CHINESE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORTALITY; OVERALL SURVIVAL; OXYGEN SATURATION; PERICARDIAL EFFUSION; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASODILATATION; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; HYPERTENSION, PULMONARY; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84907569330     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00182813     Document Type: Article

References (48)

1. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-Associated pulmonary arterial hypertension from REVEAL. Identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
2. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-Associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
3. Lau CS, Yin G, Mok MY. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus 2006; 15: 715-719.
4. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-318.
5. Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010; 19: 1365-1373.
6. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165-170.
7. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systemic literature review. Semin Arthritis Rheum 2008; 37: 223-235.
8. Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic country. Rheumatology (Oxford) 2004; 43: 1129-1137.
9. Kuo CF, See LC, Yu KH, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011; 40: 373-378.
10. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
13. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögrens syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
14. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.
15. Sharp GC. Diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Antinuclear Antibodies. Amsterdam, Excerpta Medica, 1987; pp. 23-30.
16. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
17. Mok CC, Lau CS. Lupus in Hong Kong Chinese. Lupus 2003; 12: 717-722.
18. Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther 2008; 10: R17-R27.
19. Mok CC. Epidemiology and survival of systemic lupus erythematosus inHong Kong Chinese. Lupus 2011; 20: 767-771.
20. Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. Arthritis Rheumatol 2014; 66: 357-368.
21. Andreasson K, Saxne T, Berqknut C, et al. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and proposed ACR-EULAR classification criteria, Ann Rheum Dis 2013 [In press DOI: 10.1136/annrheumdis-2013-203618].
22. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-2255.
23. Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 2012; 51: 721-729.
24. Ji YQ, Zhang ZL, Lu WX. [The clinical analysis of pulmonary arterial hypertension in connective tissue disease]. Chin J Intern Med 2006; 45: 467-471.
25. Kobayashi Y, Numano F. Takayasu arteritis. Intern Med 2002; 41: 44-46.
26. Toshihiko N. Current status of large and small vessel vasculitis in Japan. Int J Cardiol 1996; 54: Suppl., S91-S98.
27. Ren LX, Zhang FS, Yang YH, et al. [The prevalence report of Takayasu arteritis in the northern forest region of China]. J Harbin Med U 1992; 2: 116-117.
28. Watts R, Al-Taiar A, Mooney J, et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 2009; 48: 1008-1011.
29. Thakare M, Habibi S, Agrawal S, et al. Pulmonary arterial hypertension complicating adult-onset Stills disease. Clin Rheumatol 2013; 32: Suppl. 1, S1-S2.
30. Kasukawa R. Pulmonary hypertension in connective tissue disease. Intern Med 1996; 35: 1-2.
31. Galie N, Manes A, Farahani KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005; 14: 713-717.
32. Pope J. An update in pulmonary hypertension in systemic lupus erythematosus -do we need to know about it? Lupus 2008; 17: 274-277.
33. Proudman SM, Stevens WM, Sahhar J, et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 485-494.
34. Biétry O, Kieffer E, Herson S, et al. Formes artérielles pulmonaires graves de lartérite de Takayasu. Trois observations et revue de la littérature [Severe pulmonary artery involvement of Takayasu arteritis. 3 cases and review of the literature]. Ar Mal Coeur Vaiss 1991; 84: 817-822.
35. Lie JT. Isolated pulmonary Takayasu arteritis: clinicopathologic characteristics. Mod Pathol 1996; 9: 469-474.
36. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-Associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940-1946.
37. Jasi X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-And mixed connective tissue diseaseassociated pulmonary arterial hypertension: a retrospective analysis of twenty-Three cases. Arthritis Rheum 2008; 58: 521-531.
38. Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-Associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
39. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-Term survival. Arthritis Rheum 2011; 63: 3522-3530.
40. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-466.
41. Thakkar V, Stevens MW, Prior D, et al. N-Terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 2012; 14: R143-R153.
42. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349.
43. Galie N, Rubin LJ, HoeperMM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
44. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-577.
45. Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with intersititial lung disease. Chest 2011; 140: 1016-1024.
46. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
47. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43: Suppl. S, 48S-55S.
48. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002; 90: 1405-1409.